The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts ≥100,000/µL. Median progression-free survival (PFS) was 1.88 years (95% CI 1.48–2.38) for patients who developed treatment-related thrombocytopenia (<100,000/µL) within sixty days of initiation of first-line therapy, compared to 2.64 years (95% CI 2.39–2.78) in patients who did not (p =.042), while median overall survival (OS) was 5.70 years (95% CI 3.02–9.00) and 8.43 years (95% CI 6.62–9.17), respectively (p =.030). Platelet count reduction >70% from pretreatment baseline was similarly predictive of inferior PFS and OS. This is the first study to demonstrate the predictive and prognostic value of treatment-related thrombocytopenia in newly diagnosed MM.
CITATION STYLE
Mellors, P. W., Binder, M., Buadi, F. K., Lacy, M. Q., Gertz, M. A., Dispenzieri, A., … Kumar, S. K. (2019). Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leukemia and Lymphoma, 60(12), 2960–2967. https://doi.org/10.1080/10428194.2019.1613536
Mendeley helps you to discover research relevant for your work.